leisure time -WSS

leisure time

author：Wikipedia 2025-08-21 08:27:05 - browse：32681

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

entertainment

WSS

HIV vaccine remains elusive. Immunologists keep trying new ideas

Helping hospitals and community health centers plan for resilience

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Data integrity in scientific journals requires "effort" by publishers, institutions

After decades in use, heart stents finally beat placebo

Healthy food access boosts outcomes in two studies

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What is STAT's opinion section for?

Jerome Adams on the need for new antivirals for Covid

Solving academic medical centers' existential crisis

Psychedelics group wrestles with new pharma identity

NVIDIA and Google execs on the future of AI and drug discovery

Malaria cases in Florida and Texas: Here’s what you need to know

What health policies could hitch a ride on a spending bill?

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Zepbound, Valneva's vaccine, and more

leisure time

Carbon Health diabetes program, a test of data

Criminal prosecution for violating HIPAA: an emerging threat

Cytokinetics CEO stresses company can launch heart drug on its own

Ventyx halts psoriasis drug development after lackluster trial results

Medicare’s new pay boost for primary care is angering specialists

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

leisure time

focus

entertainment

explore